BRCC36 regulates β-catenin ubiquitination to alleviate vascular calcification in chronic kidney disease.

ABSTRACT:

Background

The prevalence of vascular calcification (VC) in chronic kidney disease (CKD) patients remains substantial, but currently, there are no effective pharmaceutical therapies available. BRCA1/BRCA2-containing complex subunit 36 (BRCC36) has been implicated in osteoblast osteogenic conversion; however, its specific role in VC remains to be fully elucidated. The aim of this study was to investigate the role and underlying mechanisms of BRCC36 in VC.

Methods

The association between BRCC36 expression and VC was examined in radial arteries from patients with CKD, high-adenine-induced CKD mice, and vascular smooth muscle cells (VSMCs). Western blotting, real-time polymerase chain reaction, immunofluorescence, and immunohistochemistry were used to analyse gene expression. Ga

SUBMITTER: Li Y 

PROVIDER: S-EPMC11373267 | biostudies-literature | 2024 Sep

REPOSITORIES: biostudies-literature